Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD

Chest

Volumn 146, Issue 3, 2014, Pages 611-623

  Tse, Hoi Nam ^a   Raiteri, Luca ^b   Wong, King Ying ^c   Ng, Lai Yun ^a   Yee, Kwok Sang ^c   Tseng, Cee Zhung Steven ^a  

^a KWONG WAH HOSPITAL   (Hong Kong)

^b Zambon SpA   (Italy)

^c Wong Tai Sin Hospital   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC AGENT; PLACEBO; SHORT ACTING DRUG; SCAVENGER;

AGED; ARTICLE; CHINESE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RISK PATIENT; HUMAN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; DOSE RESPONSE; ENDURANCE; HONG KONG; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRE; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

ACETYLCYSTEINE; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; FREE RADICAL SCAVENGERS; HONG KONG; HUMANS; MALE; PHYSICAL ENDURANCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84907224420     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-2784     Document Type: Article

References (41)

1. Seemungal TA, Hurst JR, Wedzicha JA. Exacerbation rate, health status and mortality in COPD-a review of potential interventions. Int J Chron Obstruct Pulmon Dis. 2009;2009(4): 203-223.
2. Vestbo J, Hurd SS, Agustí AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013; 187 (4): 347-365.
3. Sadowska AM, Manuel-Y-Keenoy B, De Backer WA. Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review. Pulm Pharmacol Ther. 2007; 20 (1): 9-22.
4. Poole P, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2010;(2): CD001287.
5. Decramer M, Rutten-van Mölken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet. 2005; 365 (9470): 1552-1560.
6. Stav D, Raz M. Effect of N-acetylcysteine on air trapping in COPD: a randomized placebo-controlled study. Chest. 2009; 136 (2): 381-386.
7. Tse HN, Raiteri L, Wong KY, et al. Highdose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013; 144 (1): 106-118.
8. Wedzicha JA, Rabe KF, Martinez FJ, et al. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Chest. 2013; 143 (5): 1302-1311.
9. Wedzicha JA, Brill SE, Allinson JP, Donaldson GC. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013; 11: 181.
10. Hurst JR, Vestbo J, Anzueto A, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010; 363 (12): 1128-1138.
11. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002; 113 (1): 59-65.
12. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999; 115 (4): 957-965.
13. Calverley PM, Anderson JA, Celli B, et al; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007; 356 (8): 775-789.
14. Vogelmeier C, Hederer B, Glaab T, et al; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011; 364 (12): 1093-1103.
15. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003; 22 (6): 912-919.
16. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359 (15): 1543-1554.
17. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371 (9629): 2013-2018.
18. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med. 1989; 6 (6): 593-597.
19. Cotgreave IA. N-acetylcysteine: pharmacological considerations and experimental and clinical applications. Adv Pharmacol. 1997; 38: 205-227.
20. Moldéus P, Cotgreave IA, Berggren M. Lung protection by a thiol-containing antioxidant: N-acetylcysteine. Respiration. 1986; 50 (suppl 1): 31-42.
21. Cotgreave IA, Moldéus P. Lung protection by thiol-containing antioxidants. Bull Eur Physiopathol Respir. 1987; 23 (4): 275-277.
22. Jeff ery PK, Rogers DF, Ayers MM. Effect of oral acetylcysteine on tobacco smokeinduced secretory cell hyperplasia. Eur J Respir Dis Suppl. 1985; 139: 117-122.
23. Rubio ML, Sanchez-Cifuentes MV, Ortega M, et al. N-acetylcysteine prevents cigarette smoke induced small airways alterations in rats. Eur Respir J. 2000; 15 (3): 505-511.
24. Bridgeman MM, Marsden M, MacNee W, Flenley DC, Ryle AP. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax. 1991; 46 (1): 39-42.
25. Bergstrand H, Björnson A, Eklund A, et al. Stimuli-induced superoxide radical generation in vitro by human alveolar macrophages from smokers: modulation by N-acetylcysteine treatment in vivo. J Free Radic Biol Med. 1986; 2 (2): 119-127.
26. Eklund A, Eriksson O, Håkansson L, et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J. 1988; 1 (9): 832-838.
27. Niederman MS, Raff erty TD, Sasaki CT, Merrill WW, Matthay RA, Reynolds HY. Comparison of bacterial adherence to ciliated and squamous epithelial cells obtained from the human respiratory tract. Am Rev Respir Dis. 1983; 127 (1): 85-90.
28. Suer E, Sayrac S, Sarinay E, et al. Variation in the attachment of Streptococcus pneumoniae to human pharyngeal epithelial cells after treatment with S-carboxymethylcysteine. J Infect Chemother. 2008; 14 (4): 333-336.
29. Riise GC, Qvarfordt I, Larsson S, Eliasson V, Andersson BA. Inhibitory effect of N-acetylcysteine on adherence of Streptococcus pneumoniae and Haemophilus influenzae to human oropharyngeal epithelial cells in vitro. Respiration. 2000; 67 (5): 552-558.
30. Sinojia R, Shaikh M, Kodgule R, et al. Priming of beta-2 agonist and antimuscarinic induced physiological responses induced by 1200mg/day NAC in moderate to severe COPD patients: a pilot study. Respir Physiol Neurobiol. 2014; 191: 52-59.
31. Wu W, Patel KB, Booth JL, Zhang W, Metcalf JP. Cigarette smoke extract suppresses the RIG-I-initiated innate immune response to influenza virus in the human lung. Am J Physiol Lung Cell Mol Physiol. 2011; 300 (6): L821-L830.
32. Benrahmoune M, Thérond P, Abedinzadeh Z. The reaction of superoxide radical with N-acetylcysteine. Free Radic Biol Med. 2000; 29 (8): 775-782.
33. Gressier B, Cabanis A, Lebegue S, et al. Decrease of hypochlorous acid and hydroxyl radical generated by stimulated human neutrophils: comparison in vitro of some thiol-containing drugs. Methods Find Exp Clin Pharmacol. 1994; 16 (1): 9-13.
34. Kharazmi A, Nielsen H, Schiøtz PO. N-acetylcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism. Int J Immunopharmacol. 1988; 10 (1): 39-46.
35. Stolarek R, Białasiewicz P, Nowak D. N-acetylcysteine effect on the luminoldependent chemiluminescence pattern of reactive oxygen species generation by human polymorphonuclear leukocytes. Pulm Pharmacol Ther. 2002; 15 (4): 385-392.
36. Bridgeman MM, Marsden M, Selby C, Morrison D, MacNee W. Effect of N-acetyl cysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax. 1994; 49 (7): 670-675.
37. De Benedetto F, Aceto A, Dragani B, et al. Long-term oral n-acetylcysteine reduces exhaled hydrogen peroxide in stable COPD. Pulm Pharmacol Ther. 2005; 18 (1): 41-47.
38. Kasielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med. 2001; 95 (6): 448-456.
39. Abdool-Gaff ar MS, Ambaram A, Ainslie GM, et al; COPD Working Group. Guideline for the management of chronic obstructive pulmonary disease-2011 update [published correction appears in S Afr Med J. 2011;101(5):288].
40. S Afr Med J. 2011;101(1 pt 2):63-73.
41. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology. 2006; 11 (5): 603-610.